EGFR and non-small cell lung carcinoma: Our results show that the cotreatment with afatinib and the CypA inhibitors, C9 or CsA, more potently inhibited the proliferation and tumorsphere formation of EGFR-mutant NSCLC CSCs than single-compound treatments, but did not suppress these processes in EGFR-wild-type NSCLC CSCs.